These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 1515258

  • 1. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial.
    Bruning PF.
    Eur J Cancer; 1992; 28A(8-9):1404-7. PubMed ID: 1515258
    [Abstract] [Full Text] [Related]

  • 2. Droloxifene, a new antiestrogen, in advanced breast cancer. A double-blind dose-finding study. The Droloxifene 002 International Study Group.
    Deschênes L.
    Am J Clin Oncol; 1991; 14 Suppl 2():S52-5. PubMed ID: 1962599
    [Abstract] [Full Text] [Related]

  • 3. European early phase II dose-finding study of droloxifene in advanced breast cancer.
    Bellmunt J, Solé L.
    Am J Clin Oncol; 1991; 14 Suppl 2():S36-9. PubMed ID: 1962595
    [Abstract] [Full Text] [Related]

  • 4. Japanese early phase II study of droloxifene in the treatment of advanced breast cancer. Preliminary dose-finding study.
    Abe O.
    Am J Clin Oncol; 1991; 14 Suppl 2():S40-5. PubMed ID: 1962596
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of advanced breast cancer in postmenopausal women with droloxifene: results of a double-blind phase II trial for dose determination].
    Chevallier B, Spielmann M, Marty M, Serin D, Pouillart P, Tubiana Hulin M, Mignot L, Pujade Lauraine E, Krams M, Mertens H.
    Bull Cancer; 1993 Jul; 80(7):624-8. PubMed ID: 8204943
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of droloxifene in patients with metastatic breast cancer.
    Buzdar AU, Kau S, Hortobagyi GN, Theriault RL, Booser D, Holmes FA, Walters R, Krakoff IH.
    Cancer Chemother Pharmacol; 1994 Jul; 33(4):313-6. PubMed ID: 8281625
    [Abstract] [Full Text] [Related]

  • 7. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
    Buzdar A, Hayes D, El-Khoudary A, Yan S, Lønning P, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, Eisenber P, Droloxifene 301 Study Group.
    Breast Cancer Res Treat; 2002 May; 73(2):161-75. PubMed ID: 12088118
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Droloxifene, a new antiestrogen: its role in metastatic breast cancer.
    Rauschning W, Pritchard KI.
    Breast Cancer Res Treat; 1994 May; 31(1):83-94. PubMed ID: 7981460
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Droloxifene, a new antiestrogen. Hormonal influences in postmenopausal breast cancer patients.
    Kvinnsland S.
    Am J Clin Oncol; 1991 May; 14 Suppl 2():S46-51. PubMed ID: 1962597
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of droloxifene and its metabolites in breast cancer patients.
    Grill HJ, Pollow K.
    Am J Clin Oncol; 1991 May; 14 Suppl 2():S21-9. PubMed ID: 1962593
    [Abstract] [Full Text] [Related]

  • 15. Phase II clinical study of high-dose toremifene in patients with advanced breast cancer.
    Modig H, Borgström S, Nilsson I, Westman G.
    J Steroid Biochem; 1990 Jun 22; 36(3):237-8. PubMed ID: 2142243
    [Abstract] [Full Text] [Related]

  • 16. Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer.
    Bishop J, Murray R, Webster L, Pitt P, Stokes K, Fennessy A, Olver I, Leber G.
    Cancer Chemother Pharmacol; 1992 Jun 22; 30(3):174-8. PubMed ID: 1385761
    [Abstract] [Full Text] [Related]

  • 17. High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative study.
    Hietanen T, Baltina D, Johansson R, Numminen S, Hakala T, Helle L, Valavaara R.
    Breast Cancer Res Treat; 1990 Aug 22; 16 Suppl():S37-40. PubMed ID: 2149284
    [Abstract] [Full Text] [Related]

  • 18. Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment.
    Haarstad H, Lønning PE, Gundersen S, Wist E, Raabe N, Kvinnsland S.
    Acta Oncol; 1998 Aug 22; 37(4):365-8. PubMed ID: 9743458
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant endocrine therapy of breast cancer--a controlled clinical trial of oestrogen and anti-oestrogen: preliminary results of the Copenhagen breast cancer trials.
    Palshof T, Mouridsen HT, Daehnfeldt JL.
    Recent Results Cancer Res; 1980 Aug 22; 71():185-9. PubMed ID: 6988914
    [Abstract] [Full Text] [Related]

  • 20. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS.
    Lancet Oncol; 2018 Jul 22; 19(7):904-915. PubMed ID: 29804902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.